Ac­tivo® Liq­uid - in vitro Trial Re­sults

The Poultry Bulletin - - LOCAL NEWS -

Is it pos­si­ble to in­hibit growth of an­tibi­otic re­sis­tant pathogens (ESBL, MRSA) by the use of Ac­tivo® Liq­uid in vitro?

Trial De­sign

In this trial four ESBL pro­duc­ing E. coli, two MRSA and the non­re­sis­tant ref­er­ence strains all iso­lated from farms were tested con­cern­ing their sen­si­tiv­ity against Ac­tivo® Liq­uid. Ev­ery bac­te­ria strain (Con­cen­tra­tion:1x104 Cfu/ml) had to un­dergo a bac­te­rial in­hi­bi­tion as­say in the ap­pro­pri­ate medium at 37°C for 6-7 hours. (Lab­o­ra­tory: Vaxxi­nova, Mün­ster)

Con­clu­sion

In this trial Ac­tivo® Liq­uid, de­pen­dent on the con­cen­tra­tions used, could show bac­te­rio­static and bac­te­ri­ci­dal ef­fects against Esbl-pro­duc­ing E. coli, MRSA, as well as the ref­er­ence strains of both bac­te­ria.

In case of ques­tions or if you need fur­ther in­for­ma­tion, please do not hes­i­tate to con­tact us: info@ew-nu­tri­tion.com. We are glad to as­sist you!

Au­thor: Timo Roth­stein, EW Nu­tri­tion Gmbh

Newspapers in English

Newspapers from South Africa

© PressReader. All rights reserved.